Interferon beta-1a-matching placebo

DRUG2 trials

Conditions

Relapsing Multiple Sclerosis

Phase 3

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

CompletedNCT01247324

Hoffmann-La RocheRelapsing Multiple Sclerosis

Start: 2011-08-31End: 2022-12-31Updated: 2024-03-04

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

CompletedNCT01412333

Hoffmann-La RocheRelapsing Multiple Sclerosis

Start: 2011-09-20End: 2022-12-30Updated: 2024-03-08

Journal of Comparative Effectiveness Research2025-09-12

Performance of Composite Endpoints Defining Progression Independent of Relapse Activity in Multiple Sclerosis

Annals of Clinical and Translational Neurology2025-07-081 citations

Uncovering a bias in estimated treatment effects on PIRA in multiple sclerosis clinical trials.

2025-06-18

Composite Confirmed Disability Worsening/Progression Is a Useful Clinical Endpoint for Multiple Sclerosis Clinical Trials

Neurology2025-04-214 citations

Cognitive effects of ocrelizumab vs interferon β-1a in relapsing multiple sclerosis: A post hoc analysis of the OPERA I/II trials.

2025-02-022 citations

Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS: Nine-Year Data From the OPERA Studies Open-Label Extension.

2025-01-3012 citations

Machine learning–based prediction of disease progression in primary progressive multiple sclerosis

Brain Communications2024-12-244 citations

Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis

Frontiers in Neurology2024-10-244 citations

Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: A propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatments

Journal of Central Nervous System Disease2024-09-132 citations

ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial

Journal of Neurology2024-04-225 citations

Ocrelizumab-treated patients with relapsing multiple sclerosis show volume loss rates similar to healthy aging

Multiple Sclerosis Journal2023-05-0111 citations

Long-Term Treatment With First-Line Ocrelizumab in Patients With Early RMS: 9-Year OPERA Subgroup Analysis (S46.002)

Neurology2023-04-253 citations

Myelin Water Fraction of Slowly Evolving Lesions is Associated With Disability in Multiple Sclerosis (P10-3.017)

Neurology2023-04-251 citations

Delayed Signs of Early Disability Progression After 8.5 Years of Ocrelizumab Treatment in Patients With Relapsing Multiple Sclerosis (S46.003)

Neurology2023-04-251 citations

Effect of Ocrelizumab on B- and T-Cell Receptor Repertoire Diversity in Patients With Relapsing Multiple Sclerosis From the Randomized Phase III OPERA Trial

Neurology Neuroimmunology & Neuroinflammation2023-04-2415 citations

Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis

Neurology Neuroimmunology & Neuroinflammation2023-02-1556 citations

Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis.

2022-07-0410 citations

Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS

Multiple Sclerosis Journal2022-06-0715 citations

020 Long-term efficacy of ocrelizumab in relapsing multiple sclerosis: 6 study years

Journal of Neurology Neurosurgery & Psychiatry2022-05-27

034 Updated safety analysis of ocrelizumab in multiple sclerosis

Journal of Neurology Neurosurgery & Psychiatry2022-05-27

26 more papers not shown

Interferon beta-1a-matching placebo

Sponsors

Conditions

Phase 3

Related Papers